Biondo Investment Advisors Has Raised Its Abiomed (ABMD) Position; Meridian Bioscience, Inc. (VIVO) Had 0 Bulls

ABIOMED, Inc. (NASDAQ:ABMD) Logo

Biondo Investment Advisors Llc increased Abiomed Inc (ABMD) stake by 4.45% reported in 2018Q1 SEC filing. Biondo Investment Advisors Llc acquired 3,105 shares as Abiomed Inc (ABMD)’s stock rose 44.33%. The Biondo Investment Advisors Llc holds 72,899 shares with $21.21 million value, up from 69,794 last quarter. Abiomed Inc now has $18.62B valuation. The stock increased 0.77% or $3.18 during the last trading session, reaching $417.12. About 42,266 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 190.17% since June 29, 2017 and is uptrending. It has outperformed by 177.60% the S&P500. Some Historical ABMD News: 05/04/2018 – ABIOMED ANNOUNCES EUROPEAN APPROVAL (CE MARKING) FOR IMPELLA 5.5(TM) AND FIRST PATIENT TREATED AT UNIVERSITY HEART CENTER HAMBURG; 03/04/2018 – Opsens Technology Receives FDA Approval in Abiomed’s Impella Cardiac Pump; 04/04/2018 – ABIOMED ANNOUNCES EUROPEAN APPROVAL (CE MARKING) FOR IMPELLA 5.5 AND FIRST PATIENT TREATED AT UNIVERSITY HEART CENTER HAMBURG; 30/03/2018 – ABIOMED INC – TODD A. TRAPP WILL BE APPOINTED AS VICE PRESIDENT AND CFO, EFFECTIVE APRIL 9, 2018; 05/04/2018 – Abiomed Announces European Approval (CE Marking) for lmpella 5.5(TM) and First Patient Treated at University Heart Center Hamburg; 03/05/2018 – Abiomed Company Marketing Scheduled By Stephens Inc for May. 10; 04/04/2018 – Abiomed Announces European Approval (CE Marking) for Impella 5.5 and First Patient Treated at University Heart Center; 03/05/2018 – Abiomed Sees FY19 Rev $740M-$770M; 30/03/2018 – ABIOMED TO NAME NEW CFO TODD A. TRAPP; 03/05/2018 – ABIOMED INC ABMD.O SEES FY 2019 REVENUE UP 25 TO 30 PCT

Among 3 analysts covering Meridian Bioscience Inc (NASDAQ:VIVO), 0 have Buy rating, 1 Sell and 2 Hold. Therefore 0 are positive. Meridian Bioscience Inc had 3 analyst reports since January 25, 2018 according to SRatingsIntel. On Thursday, January 25 the stock rating was maintained by Piper Jaffray with “Sell”. The rating was maintained by Canaccord Genuity on Thursday, January 25 with “Hold”. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) earned “Hold” rating by Robert W. Baird on Thursday, January 25. See Meridian Bioscience, Inc. (NASDAQ:VIVO) latest ratings:

25/01/2018 Broker: Piper Jaffray Rating: Sell New Target: $11.0 Maintain
25/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $16.0 Maintain
25/01/2018 Broker: Robert W. Baird Rating: Hold New Target: $16.0 Maintain

Investors sentiment decreased to 0.95 in Q1 2018. Its down 0.23, from 1.18 in 2017Q4. It dived, as 23 investors sold ABMD shares while 135 reduced holdings. 67 funds opened positions while 83 raised stakes. 36.41 million shares or 0.08% less from 36.44 million shares in 2017Q4 were reported. Vantage Investment Advisors Lc has 60 shares for 0% of their portfolio. Artemis Investment Management Llp invested 0.05% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). Moreover, Apg Asset Management Nv has 0% invested in ABIOMED, Inc. (NASDAQ:ABMD). Marshall Wace Ltd Liability Partnership owns 6,120 shares or 0.07% of their US portfolio. Stifel Finance Corp reported 0% stake. Eqis Capital accumulated 1,402 shares or 0.02% of the stock. Juncture Wealth Strategies Limited Liability Co invested 0.56% in ABIOMED, Inc. (NASDAQ:ABMD). Fred Alger Mngmt Inc holds 0.53% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD) for 388,531 shares. Credit Agricole S A reported 4,200 shares stake. Hamilton Lane Advisors Lc reported 3,685 shares. Finance Architects Inc stated it has 0.11% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). Advantus Mngmt holds 0.04% or 5,173 shares in its portfolio. Federated Investors Incorporated Pa accumulated 80,763 shares. Fmr Lc reported 515,424 shares stake. Intersect Cap Limited Com accumulated 735 shares.

Among 8 analysts covering Abiomed (NASDAQ:ABMD), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Abiomed had 11 analyst reports since January 4, 2018 according to SRatingsIntel. The firm has “Buy” rating by Stephens given on Monday, April 9. SunTrust maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Friday, February 16. SunTrust has “Buy” rating and $370.0 target. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Thursday, February 1 by Piper Jaffray. Stephens maintained it with “Buy” rating and $274.0 target in Friday, February 2 report. The stock of ABIOMED, Inc. (NASDAQ:ABMD) earned “Equal-Weight” rating by Morgan Stanley on Friday, February 2. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Thursday, January 4 by Piper Jaffray. The stock has “Buy” rating by Guggenheim on Friday, February 2. Jefferies maintained it with “Buy” rating and $300.0 target in Thursday, February 1 report. As per Tuesday, May 1, the company rating was maintained by Morgan Stanley.

Biondo Investment Advisors Llc decreased Jpmorgan Chase & Co stake by 62,192 shares to 99,860 valued at $6.95 million in 2018Q1. It also reduced Bank Amer Corp stake by 329,985 shares and now owns 518,242 shares. Jpmorgan Chase & Co (NYSE:JPM) was reduced too.

Since February 20, 2018, it had 0 insider purchases, and 7 insider sales for $98.40 million activity. $7.93M worth of ABIOMED, Inc. (NASDAQ:ABMD) was sold by BOLT WILLIAM J. Howley Michael G also sold $6.09 million worth of ABIOMED, Inc. (NASDAQ:ABMD) on Monday, May 7. 13,500 ABIOMED, Inc. (NASDAQ:ABMD) shares with value of $4.70 million were sold by PUHY DOROTHY E. On Thursday, June 21 MINOGUE MICHAEL R sold $46.17M worth of ABIOMED, Inc. (NASDAQ:ABMD) or 105,000 shares. Greenfield Andrew J sold $5.41 million worth of stock or 20,000 shares. The insider SUTTER MARTIN P sold $7.52 million. On Friday, June 15 Weber David M sold $20.58 million worth of ABIOMED, Inc. (NASDAQ:ABMD) or 46,500 shares.

More recent ABIOMED, Inc. (NASDAQ:ABMD) news were published by: Nasdaq.com which released: “Report: Developing Opportunities within ABIOMED, Avid Technology, Unit, Omeros, Strayer Education, and …” on June 21, 2018. Also Investorplace.com published the news titled: “7 A-Rated Stocks to Buy for the Second Half of 2018” on June 08, 2018. Seekingalpha.com‘s news article titled: “Discovery Is Undervalued – Cramer’s Lightning Round (6/11/18)” with publication date: June 12, 2018 was also an interesting one.

More recent Meridian Bioscience, Inc. (NASDAQ:VIVO) news were published by: Nasdaq.com which released: “Meridian Bioscience, Inc. Expects to Report Third Quarter Fiscal Year 2018 Operating Results on Tuesday, July 31, 2018” on June 01, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” on June 20, 2018. Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares” with publication date: June 19, 2018 was also an interesting one.

Investors sentiment increased to 1.62 in 2018 Q1. Its up 0.42, from 1.2 in 2017Q4. It is positive, as 10 investors sold Meridian Bioscience, Inc. shares while 45 reduced holdings. 28 funds opened positions while 61 raised stakes. 36.20 million shares or 0.87% less from 36.52 million shares in 2017Q4 were reported. Mondrian Investment Partners Ltd invested in 150,804 shares or 0.06% of the stock. Dimensional Fund Advsrs L P holds 0.01% or 1.82M shares. 199,207 were reported by D E Shaw Inc. Bancorporation Of America Corporation De, a North Carolina-based fund reported 35,942 shares. Deutsche Savings Bank Ag reported 393,116 shares. Louisiana State Employees Retirement Systems invested in 18,800 shares. Barclays Public Ltd invested in 0% or 30,492 shares. Geode Cap Management Limited Liability Company, a Massachusetts-based fund reported 737,638 shares. Royal Bancorp Of Canada holds 49,277 shares. Credit Suisse Ag reported 149,971 shares or 0% of all its holdings. Los Angeles Mngmt And Equity Research Incorporated holds 0.01% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 83,717 shares. Alliancebernstein L P has invested 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). Ajo Limited Partnership holds 433,947 shares or 0.03% of its portfolio. Manufacturers Life Insur Com The holds 32,194 shares or 0% of its portfolio. Morgan Stanley owns 324,096 shares.

Since February 7, 2018, it had 2 insider purchases, and 0 selling transactions for $28,784 activity. Shares for $14,034 were bought by McIlwraith John. The insider Rice John McCune Jr. bought $14,750.

The stock increased 0.63% or $0.1 during the last trading session, reaching $16.05. About 3,138 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has risen 6.09% since June 29, 2017 and is uptrending. It has underperformed by 6.48% the S&P500. Some Historical VIVO News: 01/05/2018 – News On Meridian Waste Solutions Inc. (MRDN) Now Under ATIS; 07/03/2018 – NJ Biz: EXCLUSIVE: Hackensack Meridian, Sloan-Kettering to form cancer-centers joint venture; 26/04/2018 – Meridian Bioscience Raises FY18 View To Rev $209M-$214M; 12/03/2018 – MERIDIAN ENERGY LTD – MERIDIAN’S FEBRUARY 2018 MONTHLY TOTAL INFLOWS WERE 148% OF HISTORICAL AVERAGE; 27/04/2018 – Meridian Debuts Career Development, Enhanced Privacy and Compliance Features; 30/04/2018 – MFS Meridian Funds – European Value Fund Adds LVMH; 26/04/2018 – MERIDIAN BIOSCIENCE INC VIVO.O SEES FY 2018 REVENUE $209 MLN TO $214 MLN; 29/05/2018 – WELLCARE TO BUY MERIDIAN FOR $2.5B; 14/03/2018 – Meridian Waste Solutions’ Attis Innovations Strikes Partnerships in Florida to Create Biomass Value from Rogued Citrus Trees and Byproducts; 21/05/2018 – INDIA’S PRECOT MERIDIAN LTD PREC.NS – MARCH QTR LOSS 80.2 MLN RUPEES VS LOSS 92.3 MLN RUPEES YR AGO

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart